H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on AC Immune SA (ACIU) today and set a price target of $11.00. The company’s shares closed last Monday at $5.02, close to its 52-week low of $4.07.
According to TipRanks.com, Fein is a 4-star analyst with an average return of 7.3% and a 48.6% success rate. Fein covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Zentalis Pharmaceuticals, and KalVista Pharmaceuticals.
Currently, the analyst consensus on AC Immune SA is a Moderate Buy with an average price target of $12.00.
See today’s analyst top recommended stocks >>
The company has a one-year high of $13.00 and a one-year low of $4.07. Currently, AC Immune SA has an average volume of 410.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AC Immune SA is a clinical stage biopharmaceutical company, which engages in developing therapeutic and diagnostic products. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.
